News

Fresenius Kabi and its license partner Formycon AG announce that the European Medicines Agency has accepted the Marketing Authorization Application for FYB202.

Fresenius Kabi announced that the European Commission (EC) granted marketing authorization for its tocilizumab biosimilar Tyenne®.

Fresenius Kabi is a Top Employer, with six countries receiving certification from the Top Employers Instititute.

Fresenius Kabi has signed an agreement with Virginia Oncology Associates to purchase the Ivenix Infusion System to deliver medications for its patients.

Fresenius Kabi’s JUMPstart Clinical Nutrition Award winner is announced at ESPEN congress: Lee Zheng Yii receives 250,000 Euro research grant for his fish oil nutrition study.

Fresenius Kabi and Lupagen Inc. have entered into an agreement for technologies designed to bring the delivery of cell and gene therapies closer to the patient.

Recently launched blood bag system not made with DEHP addresses market needs and is subject of an award-winning clinical study.

Fresenius Kabi and Formycon AG entered into a settlement agreement with Johnson & Johnson concerning FYB202, a proposed ustekinumab biosimilar in the U.S.

Explore the incredible impact of blood donation. Watch what our heroes think about during blood or plasma donation and read about our blood donation events.

Operating Companies Showing Consistent Performance; Group Simplification Delivered

Fresenius Kabi’s tocilizumab biosimilar candidate MSB11456 receives positive CHMP opinion.

Fresenius Kabi’ denosumab biosimilar candidate FKS518 shows positive clinical trial results.

Fresenius Kabi announced today the launch of its citrate-free biosimilar Idacio (adalimumab-aacf).

Today is World Blood Donor Day - find out more about the constant need for blood and plasma donations and watch the interview with Pierre Vidal.

Fresenius SE hosts Kabi Capital Markets Day Event, presenting the future path towards a sustainable value creation and strategies for #FutureFresenius.

Fresenius Kabi secures Premier's Technology Breakthrough agreement, reinforcing their unwavering dedication to innovation and excellence in healthcare.

Fresenius Kabi will be present at the Euroanaesthesia 2023 with a booth and symposium about best practice for ICU sedation and sustainable anesthesia.

Fresenius Kabi fuels nutritional research with a $100,000 grant, driving innovation in the field. Explore the steadfast commitment to advancement now.

Strong Performance Of Operating Companies in Q1/23 and Structural Simplification on Track

Watch a video about Fresenius Kabi's humanitarian efforts in ongoing earthquake relief initiatives through the donation of essential medical supplies.

Fresenius Kabi introduces a single-needle venous access option for the Amicus® Extracorporeal Photopheresis System, enhancing healthcare possibilities.

Vizient Innovative Technology contract awarded to Fresenius Kabi for the Ivenix infusion system. The contract sets terms for hospitals to buy the system.

Fresenius Kabi's compassionate humanitarian aid for Ukraine, showcasing their unwavering commitment to assisting those in need during challenging times.

Fresenius strengthens its management board team with new appointments at Fresenius Kabi and an expansion of the Human Resources and Legal department.

Fresenius sets a new direction for the future with new strategies and a new, rigorous financial framework in its press report for the fiscal year 2022.

Fresenius Kabi announces the launch of pegfilgrastim biosimilar Stimufend® in the U.S., expanding access to quality healthcare solutions against cancer.

Get inspired by Lizl Veldsman, JUMPstart winner 2019 with her research project on clinical nutrition and read her advices for future female researchers.

The Fresenius Group sends its deepest symphaties and condolences to people affected by the earthquake in Türkiye and Syria and donates lifesaving products.

Ivenix Infusion System is the subject of a recent KLAS report, showing that U.S. customers are highly satisfied with the technologically advanced system.

Fresenius Kabi and Formycon partner globally to commercialize Ustekinumab biosimilar, expanding access to affordable healthcare solutions worldwide.

Sonja Meyers idea "getAgo" a waterproof zip toiletry bag wins the queen silvia nursing award in spring 2023. Read more about the award and her idea here.

To remain a responsible and successful company, Fresenius Kabi's Vision 2026 is the foundation for a sustainable growth strategy for the next decade.

Fresenius Kabi gets U.S. FDA approval for their biosimilar Idacio®, a citrate-free formulation of adalimumab which use is for chronic autoimmune diseases.

Read more about the upcoming third wave of Fresenius Kabi's research grant in clinical nutrition, starting december 2022 and what a JUMPstart is in general.

Fresenius Kabi achieves new important milestone with the extension of the 4th MedTech manufacturing facility at PIISA in Haina in the Dominican Republic.

Weak third quarter for Fresenius Kabi due to ongoing challenging macroeconomic enviroment. Fresensius responds with realignment of business activities.

Fresenius Kabi employees in the US, Italy, France, Haina, Brasil and more have shown their commitment for Breast Cancer Awareness Month in different ways.

New Fresenius CEO Michael Sen outlines his vision for #FutureFresenius and his initial thoughts on the project in a video from the 3rd of october 2022.

Explore how Fresenius Kabi supports young patients and their families with creative learning experiences about nutritions at Children's Hospital in Cairo.

Fresenius Kabi announces that the FDA has approved its pegfilgrastim biosimilar, Stimufend® which is a high-quality treatment option for cancer patients.

Fresenius appoints Michael Sen as the successor of the former CEO Stephan Sturm. He will take up his new position at the beginning of October 2022.

Fresenius Kabi announces EMA acceptance for biosimilar MSB11456, which is a new addition to a compelling biosimilar portfolio against autoimmune diseases.

Fresenius Kabi announces a partnership with Fiocruz/Bio-Manguinhos for the production of adalimumab biosimilar, IDACIO in Brazil for autoimmune diseases.

Preliminary and financial results for the second quarter and first half of 2022 and more on how Fresenius Kabi is meeting the overall economic challenges.

The FDA has accepted for review Fresenius Kabi’s Biologics License Application for the company’s biosimilar candidate of tocilizumab.

Fresenius Kabi's successful majority stake acquisition of mAbxience marks a significant step in their commitment to healthcare innovation and excellence.

Fresenius Kabi revises outlook for group guidance 2022 due to increased wage inflation, labor shortage and overall worsened macrooeconomic enviroment.

Explore, what the Austrian broadcasting cooperation's video shoot for its series "The future makers" was like and get an insight into the Styrian industry.

For ten years Fresenius Kabi China organises nationwide blood donation activities with an increasing number. Our mission "caring for life" at its best.

Fresenius Kabi continues its efforts to provide humanitarian aid to Ukraine and recently donated about 70 pallets of urgently needed lifesaving medicines.

New data from the EuroPN study shows that early medical nutrition therapy with moderate daily calorie and protein intakes improves clinical outcomes.

Successful start for Fresenius Kabi in 2022, despite macrooeconomic challenges – Read all information about financial growth and market developements.

Fresenius Kabi completes the acquisition of Ivenix which provides state-of-the-art and industry leading offerings in infusion therapy for the U.S market.

Fresenius Kabi and the U.S. company Cerus Corporation signed a new agreement for the production of systems for pathogen inactivation in blood components.

Fresenius Kabi buys a majority stake in mAbxience and acquires Ivenix which significantly enhances their presence in high-growth biopharmaceuticals market.

Fresenius Kabi announces that the European Commission granted marketing authorization for Stimufend® which offers a high-quality option for cancer patients.

Read about the current status of humanitarian aid for Ukraine and Fresenius Kabi's contribution to the emergency treatment and care of patients on site.

Successful annual financial statements and positive outlook for fiscal year 2022 for Fresenius Kabi – Strategic evaluation shows path to accelerated growth.